Navigation Links
Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108
Date:8/5/2010

Grant awarded to Dr. Jacek Pinski to conduct the study at the Norris Comprehensive Cancer Center of the University of Southern California

QUÉBEC CITY, Aug. 5 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today announced that the National Institutes of Health ("NIH") has awarded Dr. Jacek Pinski, Associate Professor of Medicine at the Norris Comprehensive Cancer Center of the University of Southern California, a grant of about US$1.5 million over three years to conduct a Phase 1/2 study in refractory prostate cancer with the Company's doxorubicin LHRH receptor targeted conjugate compound, AEZS-108. The study, entitled "A Phase I/II Trial of AN-152 (AEZS-108) in Castration- and Taxane-Resistant Prostate Cancer", will enroll up to 55 patients and will be conducted in two portions: the first portion will be an abbreviated dose-escalation followed by a single arm, Simon Optimum two-stage design Phase 2 study using the dose selected in the Phase 1 portion. The primary objective of the Phase 2 portion is to evaluate the clinical benefit of AEZS-108 in men with castration- and taxane-resistant metastatic prostate cancer, for which the presence of LHRH receptors has been confirmed.

Juergen Engel, Ph.D., President and CEO of Aeterna Zentaris commented, "We congratulate Dr. Pinski for the grant awarded by the NIH and we are very pleased to initiate this collaboration for AEZS-108. We are excited about this study since we believ
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
2. AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
3. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
4. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
5. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
6. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
7. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
8. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
9. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
10. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
11. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... This webinar will focus on EMA and ... in biosimilars. , Regulatory frameworks are evolving many countries ... the complex nature of biopharmaceuticals makes the demonstration of ... challenging. Based on the specific aspects of biosimilar drug ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 More than ... and about 1 in 3 seniors will die with ... ). These jaw-dropping figures have shocked many Americans into ... hopefully, help prevent these tragic age-related cognitive disorders. Jonathan ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how ... latent viruses is the Epstein Barr Virus (EBV), and one ... is a chronic inflammatory disease that destroys the body’s joints. ... patients have high concentrations of EBV DNA in their bodies ...
(Date:1/15/2014)... January 15, 2014 2013 was a ... Brain State Technologies®. They saw continued independent research led ... who were awarded a $1 million grant from the ... “Brain and Behavior” a peer reviewed journal, Amy Grant ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3
... , SAN DIEGO, July 30 Cardium ... to develop a DNA-based orthobiologics product portfolio based on research ... focus on non-union bone fractures for medically-compromised patients, and spinal ... a rapidly growing segment of the orthopedics market and represents ...
... , NEW YORK, July 30 Stemline Therapeutics, ... of oncology compounds directed to cancer stem cell targets, today ... invited to present at the New Frontiers in Cancer Drug ... Development Week in Boston, MA. Dr. Bergstein,s presentation, entitled ...
... July 30 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc.,(OTC Bulletin ... developer and,producer of prescriptions drugs and licensed national ... China, today reported it received notice,of patent pending ... People,s,Republic of China for its innovative patent application ...
Cached Biology Technology:Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 2Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 3Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 4Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 5Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 6Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 7Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 8Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 9Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 10Stemline Therapeutics CEO to Present at IBC's New Frontiers in Cancer Drug Development Conference 2Lotus Pharmaceuticals, Inc. Announces Patent Pending Gliclazide-Controlled Release Tablets 2Lotus Pharmaceuticals, Inc. Announces Patent Pending Gliclazide-Controlled Release Tablets 3
(Date:4/17/2014)... are implicated in many serious conditions such as heart ... target for drug therapies. Unfortunately, there is still much ... research provides fresh and unexpected insight into the structure ... - β-subunit molecules - which are responsible for ,fine-tuning, ... in the most recent edition of the Journal ...
(Date:4/17/2014)... is the process whereby the genetic information of ... as proteins, which have numerous different functions in ... important intermediary during gene expression, by relating the ... involved in manufacturing proteins. , By examining ... present in an organism at a given time, ...
(Date:4/17/2014)... by the Australian National University (ANU), have developed ... deep-sea temperature variability over the past 5.3 million ... the climate surrounding ice ages over the past ... relationship between carbon dioxide levels, global temperatures and ... of Southampton (UoS) and the National Oceanography Centre ...
Breaking Biology News(10 mins):Structure of sodium channels different than previously believed 2Rapid and accurate mRNA detection in plant tissues 2Ancient sea-levels give new clues on ice ages 2
... to caution about the many things that could go ... contain a Southeast Asian outbreak of avian influenza in ... vaccine. , Using a computer model to simulate an ... have shown how a combination of strategies, including targeted ...
... and not the last ice age are the likely culprits ... American great mammals such as mammoths, mastodons and saber-toothed tigers, ... first arrival of humans or the warm-up of the American ... responsible for the demise of prehistoric sloths has puzzled scientists ...
... Canada in 2004 emitted about as much carbon monoxide ... during the same time period, according to new research ... fires also increased atmospheric concentrations of ground-level ozone across ... which indicates the extent to which wildfires contribute to ...
Cached Biology News:Preventing a pandemic: Study suggests strategies for containing a flu outbreak 2Preventing a pandemic: Study suggests strategies for containing a flu outbreak 3Study shows big game hunters, not climate change, killed off sloths 2Study shows big game hunters, not climate change, killed off sloths 3NCAR analysis shows widespread pollution from 2004 wildfires 2
... in a regulated environment, Pipette Tracker ... software that automates gravimetric pipette calibration ... that meets todays regulatory compliance requirements. ... solution that includes a full security ...
... AAIPharmas Routine Testing Laboratory (RTL) ... developed over 25 years. ,,Microbial method ... used to monitor the conditions of ... quality for manufactured products,,We offer a ...
... Research Scale (gram quantities of IgY) , ... Prepare your Antigen), we segregate the appropriate number ... After 3 such eggs are collected (usually over ... injection series. This involves a total of four ...
... cDNA Library Panels were designed for full-length ... of PCRs to identify the desired cDNA ... in a 96-well "Master Plate," where each ... Having identified the positive well(s) by gel ...
Biology Products: